ARID1A: a potential prognostic factor for breast cancer

Zhao, Jing; Liu, Caigang; Zhao, Zuowei

doi:10.1007/s13277-014-1632-7

Cited by 31 publications

(43 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several studies have explored the prognostic significance of ARID1A mutation or protein loss in ovarian, stomach, breast and endometrial cancers [5,6,8,9,10,11,12,13,16], no consistent relationship between ARID1A mutation or expression loss and oncologic outcome has been observed, even in the same cancer type. Only one previous study explored the prognostic impact of ARID1A loss in CRC.…”

Section: Discussionmentioning

confidence: 99%

“…The AT-rich interactive domain 1A (ARID1A), a large subunit of the SWI-SNF complex, is essential for suppression of DNA synthesis and normal cell cycle arrest [3]. Since Wiegand et al [1] proposed a role of ARID1A as a tumor suppressor in endometrial cancer, numerous studies have investigated the significance of ARID1A mutation and loss of expression in diverse tumor types, including ovarian, endometrial and breast cancers [4,5,6,7,8,9,10,11]. The documented findings widely support the theory that ARID1A functions as a tumor suppressor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Loss of AT-Rich Interactive Domain 1A Expression in Gastrointestinal Malignancies

et al. 2014

View full text Add to dashboard Cite

Objective: AT-rich interactive domain 1A (ARID1A) has recently been identified as a novel tumor suppressor in various tumor types. This study was designed to explore the clinical relevance and prognostic impact of ARID1A expression loss in colorectal cancer (CRC) and gastric cancer (GC). Methods: Immunohistochemistry for ARID1A was performed using tissue microarray blocks containing 196 CRCs and 275 GCs, along with paired normal mucosa. Data on clinicopathologic variables and oncologic outcomes of patients were collected and analyzed. Results: We identified 6.1% (12/196) CRC and 8.0% (22/275) GC cases showing loss of ARID1A expression. Expression of ARID1A in paired mucosal epithelial cells was normal in all patients. Loss of ARID1A expression was significantly correlated with negative lymphatic invasion (p = 0.003) in CRC, with large tumor size (p = 0.037) in GC, and with expanding tumor border in both tumor types (CRC, p = 0.010; GC, p = 0.031). However, no association was evident between ARID1A expression and 5-year overall survival in both tumor types. Conclusions: Loss of ARID1A expression is uncommon and not associated with oncologic outcome but may be related to less invasive clinicopathologic features in CRC and GC. Further studies with a larger number of subjects are needed to establish the possible prognostic impact of ARID1A expression loss. © 2014 S. Karger AG, Basel

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Loss of AT-Rich Interactive Domain 1A Expression in Gastrointestinal Malignancies

et al. 2014

View full text Add to dashboard Cite

show abstract

“…ARID1A mutations are frequently detected in a wide variety of gynecological and non-gynecological cancers including ovarian, endometrial, and breast carcinomas (8,10,(12)(13)(14)(15)). In addition, ARID1A mutations have been recently implicated as a possible key mechanism and early step in the carcinogenesis of ovarian clear cell and endometrioid carcinomas (15).…”

Section: Discussionmentioning

confidence: 99%

Differences in the ARID‐1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix

Kahraman

Diniz

Sayhan

et al. 2015

APMIS

View full text Add to dashboard Cite

AT-rich interactive domain 1A (ARID1A) is a tumor suppressor gene involved in chromatin remodeling which encodes ARID1A (BAF250a) protein. Recent studies have shown the loss of ARID1A expression in several types of tumors. This retrospective study was designed to evaluate the differences in tissue expressions of ARID1A in a spectrum of cervical neoplasms. Cervical intraepithelial neoplasms, invasive squamous or adenosquamous carcinomas were identified in 100 patients recently diagnosed as cervical neoplasms based on pathology databases. In this series, there were 29 low- and 29 high-grade cervical intraepithelial neoplasms, 27 squamous cell carcinomas, and 15 adenosquamous carcinomas. Mean age of the patients was 47.8 ± 13 years (20-80 years). It was determined that the expression of ARID1A was statistically significantly down-regulated in adenosquamous carcinomas when compared with non-invasive or invasive squamous cell carcinomas (p = 0.015). Lower levels of the ARID1A expression were detected in cases with adenosquamous carcinomas (60%), low- or high-grade squamous intraepithelial lesion (SIL) (31%), and squamous cell carcinomas (18.5%). Our findings have demonstrated the presence of a correlation between ARID1A expression and adenomatous differentiation of uterine squamous cell carcinomas. Therefore, ARID1A gene may suggestively have a role in the pathogenesis of cervical adenosquamous carcinomas.

show abstract

“…Previously, tumor suppressor gene p53 has been used to enhance radiotherapy effectiveness in oral cancer patients following resection surgery of tumor lesions (6,7). B-cell translocation gene 2 (BTG2) proteins were reported to be putative tumor suppressor genes, and constitute a p53-dependent component of the DNA damage cellular response pathway (8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Expression of B-cell translocation gene 2 is associated with favorable prognosis in hepatocellular carcinoma patients and sensitizes irradiation-induced hepatocellular carcinoma cell apoptosis in vitro and in nude mice

Chen¹,

Chen²,

Zhang³

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. B-cell translocation gene 2 (BTG2) proteins have been reported to be putative tumor suppressors in various cancer types. The present study first assessed BTG2 expression in 44 human liver cancer tissue specimens, then investigated BTG2 expression in the regulation of hepatocellular carcinoma (HCC) cell apoptosis with or without radiotherapy in vitro and in vivo. The results revealed that BTG2 protein expression was significantly reduced in HCC tissues, and associated with better survival for HCC patients (P=0.05). BTG2 overexpression also sensitized Huh7 cells to radiation-induced apoptosis in vitro and in a nude mouse model, although restoration of BTG2 expression per se did not affect the viability and apoptosis of HCC cells. Future studies would confirm the role of BTG2 in hepatoma, and further develop BTG2 as a therapeutic strategy for controlling HCC.

show abstract

ARID1A: a potential prognostic factor for breast cancer

Cited by 31 publications

References 20 publications

Loss of AT-Rich Interactive Domain 1A Expression in Gastrointestinal Malignancies

Loss of AT-Rich Interactive Domain 1A Expression in Gastrointestinal Malignancies

Differences in the ARID‐1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix

Expression of B-cell translocation gene 2 is associated with favorable prognosis in hepatocellular carcinoma patients and sensitizes irradiation-induced hepatocellular carcinoma cell apoptosis in vitro and in nude mice

Contact Info

Product

Resources

About